PTC THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.25 USD | +3.86% |
|
-2.30% | +17.02% |
| Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
| Apr. 29 | Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 | MT |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the PIVOT-HD interim ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
32.25
USD
Average target price
29.5
USD
Spread / Average Target
-8.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.02% | 2.47B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- Transcript : PTC Therapeutics, Inc. - Special Call